scholarly journals The diagnostic value of supine blood pressure in hypertension

2016 ◽  
Vol 2 ◽  
pp. 310-318 ◽  
Author(s):  
Paweł Krzesiński ◽  
Adam Stańczyk ◽  
Grzegorz Gielerak ◽  
Katarzyna Piotrowicz ◽  
Małgorzata Banak ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Diagnostic Value ◽  
Supine Blood Pressure

scholarly journals Comparison of Urinary Adiponectin in the Presence of Metabolic Syndrome in Peri- and Postmenopausal Women

2021 ◽  
Author(s):  
Patsama Vichinsartvichai ◽  
Rattana Teeramara ◽  
Titima Jirasawas ◽  
Prirayapak Sakoonwatanyoo
Keyword(s):  
Blood Pressure ◽  
Metabolic Syndrome ◽  
Postmenopausal Women ◽  
Demographic Data ◽  
Diagnostic Value ◽  
Cross Sectional Study ◽  
Sectional Study ◽  
Cross Sectional ◽  
Screening And Diagnosis ◽  
Baseline Demographic

Abstract Objectives To find the association between urinary adiponectin and metabolic syndrome (MetS) in peri- and postmenopausal women and its potential application as a noninvasive screening for MetS. Methods A cross-sectional study was conducted in healthy peri- and postmenopausal women (defined by STRAW+10 staging) age at least 40 years who attended annual checkup or menopause clinic were recruited. Baseline demographic data, MENQOL, anthropometric measurements, blood pressure, laboratory (FBS, total cholesterol, HDL-C, LDL-C, TG) and urinary adiponectin were collected. The MetS was diagnosed according to JIS 2009. Results 290 peri- and postmenopausal women had participated. The prevalence of Mets among our participants was 18%. Urinary adiponectin levels were similar in peri- and postmenopausal women with and without MetS (2.6±2.2 vs 2.3±1.9 ng/mL, respectively, P = 0.55). Urinary adiponectin provides no diagnostic value for MetS (AUC = 0.516). Conclusions Urinary adiponectin has no role in screening and diagnosis of MetS in peri- and postmenopausal women. The quest toward noninvasive screening for MetS is still going on.

scholarly journals Pituitary Cachexia with Disturbance of Circulatory Regulation. Result of Treatment with Prolan

1935 ◽  
Vol 28 (7) ◽  
pp. 925-932 ◽  
Author(s):  
C. Stanton Hicks ◽  
F. Sandiland Hone
Keyword(s):  
Blood Pressure ◽  
Anterior Pituitary ◽  
Fat Metabolism ◽  
Diagnostic Value ◽  
Metabolic Effect ◽  
Circulatory Response ◽  
Pituitary Dysfunction ◽  
Glucose Tolerance Tests ◽  
The Subject ◽  
Muscular Effort

A case of extreme wasting associated with amenorrhœa for eighteen months. On finding that the subject showed a fall of blood-pressure with unaltered pulse-rate on sitting up, anterior pituitary dysfunction (Simmonds' syndrome (?)) was diagnosed and prolan (Bayer) was administered. Following 100 units intramuscularly administered, the circulatory response became normal in twenty-four hours. The pulse rapidly improved in strength and all circulatory symptoms disappeared within a week. Weight increased at first rapidly, and the nutrition, skin and hair improved remarkably. Metabolism of sugar, as shown by glucose tolerance tests, became normal, and evidence for improvement in fat metabolism is brought forward. The study of the case goes to support the conclusion of Schellong that a function of the anterior pituitary is to influence the circulatory response to muscular effort. That hypotonia of itself is not responsible for the circulatory symptoms is shown by the failure of ephedrine (which raised the blood-pressure) to remove the circulatory symptoms. Contrary to some accepted beliefs, prolan, which is prepared from urine of pregnant mares, has a profound metabolic effect, as well as an effect on the ovary. The diagnostic value of the circulatory response in doubtful cases is discussed.

The Addition of Visken to Methyldopa Therapy in Hypertension: A Multicentre Study

1976 ◽  
Vol 4 (2) ◽  
pp. 128-131 ◽  
Author(s):  
J E Murphy
Keyword(s):  
Blood Pressure ◽  
Side Effects ◽  
Multicentre Study ◽  
Treatment Regimen ◽  
Sleep Disturbances ◽  
Supine Blood Pressure ◽  
Blood Pressures

Forty-one patients completed the study where Visken was added to the treatment regimen of patients whose blood pressures were poorly controlled on methyldopa or who were experiencing side-effects with methyldopa. Supine blood pressure was reduced from 177/108 mm Hg before Visken therapy to 159/96 mm Hg after twelve weeks of taking Visken. The dose of methyldopa was reduced from a mean 921 mg at the start to 445 mg at the end. Fourteen patients were able to stop methyldopa therapy. The number of side-effects reported was reduced as the study continued and fifteen patients commented that they felt better on Visken. Nine patients did not complete the trial, three of these because of side-effects, viz insomnia, lethargy and sleep disturbances.

Droxidopa improves orthostatic intolerance symptoms in low and normal supine blood pressure phenotypes of vasovagal syncope

2015 ◽  
Vol 192 ◽  
pp. 100 ◽  
Author(s):  
S.J. Corcoran ◽  
C.I. Sari ◽  
E. Lambert ◽  
N.E. Straznicky ◽  
G. Hamilton ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Orthostatic Intolerance ◽  
Vasovagal Syncope ◽  
Supine Blood Pressure

scholarly journals Feasibility of adenosine stress cardiovascular magnetic resonance perfusion imaging in patients with MR-conditional transvenous permanent pacemakers and defibrillators

2022 ◽  
Vol 24 (1) ◽  
Author(s):  
Anna Giulia Pavon ◽  
Alessandra Pia Porretta ◽  
Dimitri Arangalage ◽  
Giulia Domenichini ◽  
Tobias Rutz ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Magnetic Resonance ◽  
Image Quality ◽  
Diagnostic Value ◽  
Implantable Devices ◽  
Adenosine Stress ◽  
Stress Perfusion ◽  
Mr Conditional ◽  
Stress Cmr ◽  
Perfusion Cmr

Abstract Background The use of stress perfusion-cardiovascular magnetic resonance (CMR) imaging remains limited in patients with implantable devices. The primary goal of the study was to assess the safety, image quality, and the diagnostic value of stress perfusion-CMR in patients with MR-conditional transvenous permanent pacemakers (PPM) or implantable cardioverter-defibrillators (ICD). Methods Consecutive patients with a transvenous PPM or ICD referred for adenosine stress-CMR were enrolled in this single-center longitudinal study. The CMR protocol was performed using a 1.5 T system according to current guidelines while all devices were put in MR-mode. Quality of cine, late-gadolinium-enhancement (LGE), and stress perfusion sequences were assessed. An ischemia burden of ≥ 1.5 segments was considered significant. We assessed the safety, image quality and the occurrence of interference of the magnetic field with the implantable device. In case of ischemia, we also assessed the correlation with the presence of significant coronary lesions on coronary angiography. Results Among 3743 perfusion-CMR examinations, 66 patients had implantable devices (1.7%). Image quality proved diagnostic in 98% of cases. No device damage or malfunction was reported immediately and at 1 year. Fifty patients were continuously paced during CMR. Heart rate and systolic blood pressure remained unchanged during adenosine stress, while diastolic blood pressure decreased (p = 0.007). Six patients (9%) had an ischemia-positive stress CMR and significant coronary stenoses were confirmed by coronary angiography in all cases. Conclusion Stress perfusion-CMR is safe, allows reliable ischemia detection, and provides good diagnostic value.

Significance of Brain Natriuretic Peptide Measurement as a Diagnostic Indicator of Cardiac Function

2000 ◽  
Vol 39 (03) ◽  
pp. 249-253 ◽  
Author(s):  
N. Iida ◽  
T. Ishihara ◽  
S. Waku
Keyword(s):  
Heart Failure ◽  
Blood Pressure ◽  
Brain Natriuretic Peptide ◽  
Natriuretic Peptide ◽  
Diagnostic Value ◽  
Left Ventricular ◽  
Control Group ◽  
Healthy Control ◽  
Group 5 ◽  
Lv Diastolic Dysfunction

AbstractBrain natriuretic peptide (BNP) is increased in patients with heart failure due to myocardial infarction and cardiac hypertrophy, in proportion to the severity of left ventricular dysfunction. The aims of this study were to clarify the clinical features of BNP and to determine the diagnostic value of BNP for mass screening.The subjects were 818 office workers (565 males and 253 females; mean age 47 ± 12 years) who participated in a 1996 routine health check at Kansai University All individuals were examined for blood pressure, serological findings, ECG and plasma BNP level. Thirty-three males underwent 2-D echocardiography. Plasma BNP levels were measured using IRMA (immunoradiometric assay).The results were as follows: (1) BNP levels in females were higher than those in males for healthy subjects (N = 551), in each age group from 20 to 60 years. (2) BNP levels increased with age. (3) There were significant correlations between BNP level and systolic blood pressure and creatinine level. (4) There were significant differences in BNP level between the hypertensive groups with and without hypertensive ECG changes and the age-matched healthy control group. (5) Marked correlations were observed between BNP level and left ventricular wall thickness, fractional shortening, deceleration time and peak early filling velocity. (6) A BNP cut-off-point of 25 pg/ml was best for detecting LV diastolic dysfunction and LV hypertrophy. Measurement of BNP is useful for detecting asymptomatic heart failure in the general population, and is a clinical marker useful in preventing symptomatic heart failure.

Sign in / Sign up

Export Citation Format

Share Document